Guidelines
Polverino E, Goeminne P, McDonnel M, et al. European respiratory society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50(3):1700629. These guidelines describe appropriate investigation and treatment strategies by posing nine key clinical questions and conducting systematic reviews to answer the questions.
Therapeutics
O’Donnell AE, Barker AF, Ilowite JS, et al. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. Chest 1998;113:1329-1334. A large multinational trial of patients with idiopathic bronchiectasis found increased exacerbation frequency and a more brisk decrease in FEV1. While noteworthy for its specific findings, this study is widely cited as a reason cystic fibrosis treatment strategies cannot be universally applied to all types of bronchiectasis.
Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA. 2013;309:1251-9. A trial of chronic azithromycin treatment in patients with stable non-cystic fibrosis bronchiectasis. Azithromycin was associated with a decreased pulmonary exacerbation rate but increased macrolide resistance.
